Catalent, Inc. (NYSE:CTLT) Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. boosted its position in shares of Catalent, Inc. (NYSE:CTLT) by 2.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,133 shares of the company’s stock after purchasing an additional 229 shares during the period. Crossmark Global Holdings Inc.’s holdings in Catalent were worth $553,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after acquiring an additional 2,299,784 shares during the last quarter. Magnetar Financial LLC bought a new position in Catalent during the 1st quarter valued at $56,429,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Catalent during the 2nd quarter valued at $29,172,000. Bank of Montreal Can boosted its stake in Catalent by 222.0% during the 2nd quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock valued at $36,219,000 after acquiring an additional 444,084 shares during the last quarter. Finally, Beryl Capital Management LLC bought a new position in Catalent during the 1st quarter valued at $23,756,000.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CTLT. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Thursday. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Trading Up 0.3 %

Shares of NYSE:CTLT opened at $59.10 on Friday. The company has a market cap of $10.73 billion, a PE ratio of -26.15, a P/E/G ratio of 2.35 and a beta of 1.16. The company’s 50-day moving average price is $59.84 and its 200 day moving average price is $58.20. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) earnings per share. Sell-side analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. Company insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.